Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 47-14 BRAVO 

A phase III, randomized, open label, multicenter, controlled trial of
niraparib versus physician’s choice in previously-treated, HER2
negative, germline BRCA mutation-positive breast cancer
patients.

Study Chairs
Nick Turner
Dr. Marco Colleoni, EIO, Milano, Italy

Statistician
Jan Bogaerts

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Poonam Jani 

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg47_BRAVO@fstrf.org

Date of Activation
April 1, 2014

Targeted Accrual
306


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print